Actively Recruiting
Innate Immune Response Monitoring Via Monocyte HLA-DR in Severe Intra-abdominal Infections at Risk of Fungal Infection
Led by Central Hospital, Nancy, France · Updated on 2026-02-09
100
Participants Needed
1
Research Sites
67 weeks
Total Duration
On this page
Sponsors
C
Central Hospital, Nancy, France
Lead Sponsor
H
Hospices Civils de Lyon
Collaborating Sponsor
AI-Summary
What this Trial Is About
Intra-abdominal candidiasis (IAC) is a frequent and severe fungal infection in critically ill patients, often diagnosed late. Its pathophysiology remains unclear, particularly regarding why some patients develop invasive infection while others only show benign colonization. A potential explanation lies in the state of innate immunity. Monocyte HLA-DR expression, a recognized marker of immune suppression in critical care, may be transiently but profoundly reduced in non-immunocompromised patients who go on to develop IAC. This observational study aims to evaluate whether patients with IAC have greater innate immune dysfunction-assessed by HLA-DR expression-compared to those with severe bacterial intra-abdominal infections. The goal is to better understand the immune mechanisms involved and improve early risk stratification for IAC.
CONDITIONS
Official Title
Innate Immune Response Monitoring Via Monocyte HLA-DR in Severe Intra-abdominal Infections at Risk of Fungal Infection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient (≥ 18 years old)
- Admitted to ICU or intermediate care for severe intra-abdominal infection requiring urgent abdominal surgery
- Presence of at least one risk factor for intra-abdominal candidiasis: abdominal surgery within last 7 days, supramesocolic gastrointestinal perforation, healthcare-associated intra-abdominal infection, community-acquired intra-abdominal infection in an immunocompromised patient, intra-abdominal infection complicated by septic shock, or broad-spectrum antibiotic exposure within 72 hours prior to surgery
- And/or a Peritonitis Score ≥ 3 out of 4
- Affiliated with or benefiting from a national health insurance system
- Fully informed about the clinical study
You will not qualify if you...
- Radiologically guided drainage without surgery
- Infected acute pancreatitis
- Limitation or withdrawal of life-sustaining treatments
- Moribund patient with expected life expectancy < 48 hours
- Woman of childbearing potential without effective contraception
- Refusal to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHRU de NANCY
Vandœuvre-lès-Nancy, France, 54500
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here